Metagenomics Sequencing Market

Global Metagenomics Sequencing Market is valued at USD 1052.3 Million in 2020 and expected to reach USD 3982.3 Million by 2027 with a CAGR of 18.1% over the forecast period. 

Global Metagenomics Sequencing Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027- Growing advanced technological platforms & improved genomic tools, rising initiatives and funds by government and private organizations to large scale project of sequencing and increasing prevalence of genetic disorders are the some of the major factors driving the growth of Global Metagenomics Sequencing Market.

Scope:

Metagenomics is the study of genomes in a microbial community in general. This methodology involves studying and cloning genomes without developing organic entities from the community. The metagenomics method has brought about significant upgrades in microbial nature, evolution, and variety; this activity is presently mostly carried out in many examination labs. Sequence-based metagenomics involves sequencing metagenomes and analyzing downstream information. Metagenomic sequencing permits researchers to extensively test all genes in all organic entities present in a given complex sample. The strategy empowers microbiologists to assess bacterial variety and identify the wealth of organisms in different environments. Over the most recent 20 years, this has gotten generally utilized and dug in. This procedure is more useful because it gives data pretty much all likely exercises of microorganisms addressed by the metagenome instead of simply a subset of those designated by functional screening, permitting for adaptability and freedom from the accessibility of high-throughput screening systems.

COVID-19 pandemic has shown a positive impact on the growth of the global metagenomics sequencing market. Growing in number of Covid-19 cases has prompted rapid testing and clinical diagnosing. Most of this testing is PCR-based. Next-generation sequencing (NGS) and entire genome sequencing of the Covid-19 infection are giving metagenomics information of diagnostic test that is joined with clinical information to look for efficient treatments. This factor has supported the worldwide metagenomics sequencing market.

Global metagenomics sequencing market is segmented on the basis of product & services, technology, application and regional & country level. On the basis of product & services, the metagenomics sequencing market has been classified into reagents & consumables, instruments, services and analysis & data interpretation solutions. On the basis of technology, the market has been classified into shotgun metagenomics sequencing, metatranscriptomics, 16s rRNA sequencing, whole genome sequencing & De Novo assembly. On the basis of application, the global metagenomics sequencing market has been divided into clinical diagnostics, drug discovery, biofuel, industrial applications, veterinary applications, ecological & environmental metagenomics and others.

Key Players:

Some of the key players in global metagenomics sequencing market are 

• Illumina Inc.
• Promega Corporation
• Novogene Co. Ltd.
• Takara Bio Inc
• Oxford Nanopore Technologies
• Arc Bio LLC
• Eurofins Scientific
• Zymo Research
• Microsynth AG
• Hoffmann-La Roche Ltd. (Roche Sequencing)
• PerkinElmer
• Computomics GmbH and others.

Segmentation:

By Product & Service:

• Reagents & Consumables
• Instruments
• Services
• Analysis & Data Interpretation Solutions

By Technology:

• Shotgun Metagenomics Sequencing
• Metatranscriptomics
• 16s rRNA Sequencing
• Whole Genome Sequencing & De Novo Assembly

By Application:

• Clinical Diagnostics
• Drug Discovery
• Biofuel
• Industrial Applications
• Veterinary Applications
• Ecological & Environmental Metagenomics
• Others

The regions covered in global metagenomics sequencing market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global metagenomics sequencing is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.

News: 

SYNLAB and Microba Signed Strategic Agreement to Launch Advanced Gut Microbiome Test MyBiome

July 16^th, 2020; SYNLAB, have signed a strategic agreement to launch the gut microbiome test MyBiome in Europe and LATAM. MyBiome will be an innovative and one of the most comprehensive metagenomic sequence-based tests available in the market, allowing an objective and actionable analysis of an individual’s gut microbiome.

Increasing Number of Advanced Technological Platforms & Improved Genomic Tools, Rising Initiatives and Funds by Government and Private Organizations to Large Scale Project of Sequencing and Increasing Prevalence of Genetic Disorders are Some of the Major Factors Driving the Market Growth

One of the major factors driving the growth of global metagenomics sequencing market is increasing number of advanced technological platforms & improved genomic tools. The continuous improvement of quicker sequencing techniques and developments in various techniques to adapt to the huge information generated, are increasing the analysts' ability to analyze microbial networks from a limitless assortment of environments. The developing reception of advanced bioinformatics tools, high throughput screening (HTS) strategies, recuperation of novel medications, and improvement of cost-effective innovations like next-generation sequencing (NGS) are driving the market development. For instance; on May 28^th, 2019; an exactness medication biotechnology organization, Macrogen, Inc. gotten South Korean accreditation of Good Clinical Lab Practices from the country's Ministry of Food and Drug Safety (MFDS) and assigned as a clinical preliminary specimen analysis institution. It would help Macrogen with improvised clinical diagnostic metagenomics.

In addition, rising number of initiatives and funds by government and private organizations to large scale project of sequencing is also fostering the market growth. The rising awareness regarding the genetic issues and increasing number of government funds and initiatives for large-scale projects of sequencing are among the main consideration driving the development of the worldwide metagenomic sequencing market. For example; in 2019, QIAGEN got into an association with different associations in the UK to help and build up its worldwide genomics campus in Manchester (UK). The new Genomic Health Innovation Campus will focus on advancement in translational sciences, life sciences, and the atomic diagnostics field.

Furthermore, increasing prevalence of genetic disorders also drives the global metagenomics sequencing market. A genetic disorder is hereditary medical state caused by a DNA abnormality. Metagenomics sequencing helps to reduce such abnormalities. However, lack of skilled professionals and rising concern about the standardization and accuracy of diagnostic testing may hamper the market growth. In spite of that, accessibility of cloud computing for data management can provide various opportunities for the further growth of the global metagenomics sequencing market.

North America is Expected to Dominate the Global Metagenomics Sequencing Market

North America is expected to dominate the metagenomics sequencing market within the forecast period due to rapid adoption of novel sequencing technologies, initiatives by government and private bodies for the growth, adoption of NGS-based metagenomics technologies and presence of key players in the region. For instance; in March 2019, Lundbeck Foundation GeoGenetics Center (Denmark) and Illumina cooperated to make quite possibly the most broad antiquated genome collections. This collaboration will likewise help with the examination of the developmental history of precise mental and neurological diseases and infectious microorganisms. Asia Pacific is expected to show a fastest growth in the global metagenomics sequencing market attributed to the increasing research and development activities in this field in this region.

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • France
  • Germany
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
• Latin America
  • Brazil
  • Mexico

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2021 - 2027
Market Size in 2020:	USD 1052.3 Million
Base year considered	2020
Forecast Period CAGR %:	18.1%
Market Size Expected in 2027:	USD 3982.3 Million
Tables, Charts & Figures:	175
Pages	200
Key Players/Companies	Illumina, Inc., Promega Corporation, Novogene Co., Ltd., Takara Bio, Inc, Oxford Nanopore Technologies, Arc Bio, LLC, Eurofins Scientific, Zymo Research, Microsynth AG, F. Hoffmann-La Roche Ltd. (Roche Sequencing), PerkinElmer, Inc. Computomics GmbH and others.
Segments Covered	By Product & Service, By Technology, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa